EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles

Muhammad Nawaz iD, Benyapa Tangruksa, Sepideh Heydarkhan-Hagvall, Franziska Kohl, Hernán González-King Garibotti iD, Yujia Jing, Zahra Payandeh, Azadeh Reyahi, Karin Jennbacken, John Wiseman, Leif Hultin, Lennart Lindfors und 2 weitere

Journal of Extracellular Vesicles · 2026-06 · 15 (6)

DOI: 10.1002/jev2.70324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 11.06.2026. Verfasst von Muhammad Nawaz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Extracellular Vesicles, RNA, Messenger, Nanoparticles, Myocardium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Swedish Research Council, the Swedish Foundation of Strategic Research (SSF) in the Industrial Research Centre (FoRmulaEx-Nucleotide Functional Drug Delivery, the Swedish governmental agency for innovation systems.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efficient and specific delivery of mRNA to target tissues is critical for maximising therapeutic benefits while minimising off‐target effects and systemic toxicity. Systemic administration of mRNA using lipid nanoparticles (LNPs) or extracellular vesicles (EVs) typically leads to predominant accumulation in the liver. We hypothesised that cardiac‐specific EVs could promote enhanced relative cardiac enrichment of delivered mRNA compared with non‐cardiac EVs or LNPs. In mice, intravenous administration of cardiac progenitor cell‐derived EVs (CPC‐EVs) achieved the greatest relative cardiac selectivity of modified mRNA encoding vascular endothelial growth factor A (VEGF‐A) to the heart, with reduced liver accumulation relative to non‐cardiac EVs and LNPs. Cytokine profiling across seven organs revealed that LNP delivery triggered a widespread pro‐inflammatory response, whereas CPC‐EVs elicited only a localised and limited cytokine activation, suggesting a more favourable safety profile. Furthermore, direct intramyocardial injection of CPC‐EVs not only led to efficient mRNA uptake by cardiac tissue and robust VEGF‐A protein expression, but also minimal transcriptomic perturbation in the cardiac tissue, as confirmed by RNA‐seq. In contrast, LNPs and non‐cardiac EVs induced widespread perturbation in the transcriptome of cardiac tissue. Functionally, VEGF‐A mRNA delivery via CPC‐EVs markedly increased CD31 and α‐SMA expression and vessel formation in ex vivo aortic ring assays, confirming enhanced angiogenic potential. Together, these findings support CPC‐EVs as a promising platform for achieving enhanced cardiac delivery of mRNA, with reduced liver accumulation, limited off‐target transcriptomic perturbation, a more selective cytokine response, and enhanced angiogenic activity in ex vivo assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesRNA, MessengerNanoparticlesMyocardiumAnimalsMiceVascular Endothelial Growth Factor AMaleMice, Inbred C57BLLiverLipidsStem CellsLiposomes

Stichwörter der Autor:innen

VEGF‐Aextracellular vesicleslipid nanoparticlessystemic administrationtargeted mRNA delivery

Substanzen

RNA, MessengerVascular Endothelial Growth Factor ALipid NanoparticlesLipidsLiposomes

Autor:innen und Institutionen

  • Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden.
  • Chief Medical Office, Global Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solna, Stockholm, Sweden.
  • Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Muhammad Nawaz, Hernán González-King Garibotti, Hadi Valadi

Förderung

  • the Swedish Research Council
  • the Swedish Foundation of Strategic Research (SSF) in the Industrial Research Centre (FoRmulaEx-Nucleotide Functional Drug Delivery
  • the Swedish governmental agency for innovation systems
  • VINNOVA
  • the Swedish Knowledge Foundation
  • Science for Life (SciLife) Laboratory
  • the European Union's Horizon 2020 research and innovation program
  • Stiftelsen för Strategisk Forskning

Zitieren

APA

Nawaz, M., Tangruksa, B., Heydarkhan-Hagvall, S., Kohl, F., Garibotti, H. G., Jing, Y., Payandeh, Z., Reyahi, A., Jennbacken, K., Wiseman, J., Hultin, L., Lindfors, L., Synnergren, J., & Valadi, H. (2026). Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles. Journal of Extracellular Vesicles, 15(6). https://doi.org/10.1002/jev2.70324

Vancouver

Nawaz M, Tangruksa B, Heydarkhan-Hagvall S, Kohl F, Garibotti HG, Jing Y, et al. Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles. Journal of Extracellular Vesicles. 2026;15(6). doi:10.1002/jev2.70324

BibTeX
@article{Nawaz2026,
  author = {Nawaz, Muhammad and Tangruksa, Benyapa and Heydarkhan-Hagvall, Sepideh and Kohl, Franziska and Garibotti, Hernán González-King and Jing, Yujia and Payandeh, Zahra and Reyahi, Azadeh and Jennbacken, Karin and Wiseman, John and Hultin, Leif and Lindfors, Lennart and Synnergren, Jane and Valadi, Hadi},
  title = {Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles},
  journal = {Journal of Extracellular Vesicles},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/jev2.70324}
}
Kostenlos starten →